Atea Pharmaceuticals, Inc.
AVIR
$6.00
$0.091.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 72.19% | 42.43% | 19.58% | 18.38% | -12.25% |
| Gross Profit | -72.19% | -42.43% | -19.58% | -18.38% | 12.25% |
| SG&A Expenses | -32.73% | -16.84% | -11.65% | -6.98% | -2.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.58% | -3.03% | -11.21% | -11.56% | 31.18% |
| Operating Income | -5.58% | 3.03% | 11.21% | 11.56% | -31.18% |
| Income Before Tax | 1.76% | 15.47% | 22.68% | 14.77% | -24.10% |
| Income Tax Expenses | -766.16% | -20.78% | -17.53% | -14.73% | -9.14% |
| Earnings from Continuing Operations | 5.96% | 15.51% | 22.65% | 14.77% | -23.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.96% | 15.51% | 22.65% | 14.77% | -23.85% |
| EBIT | -5.58% | 3.03% | 11.21% | 11.56% | -31.18% |
| EBITDA | -5.60% | 3.04% | 11.23% | 11.59% | -31.28% |
| EPS Basic | 2.38% | 14.34% | 23.25% | 15.73% | -22.67% |
| Normalized Basic EPS | -17.27% | -4.23% | 8.55% | 10.45% | -42.52% |
| EPS Diluted | 2.38% | 14.34% | 23.25% | 15.73% | -22.67% |
| Normalized Diluted EPS | -17.27% | -4.23% | 8.55% | 10.45% | -42.52% |
| Average Basic Shares Outstanding | -3.25% | -1.07% | 0.83% | 1.24% | 1.05% |
| Average Diluted Shares Outstanding | -3.25% | -1.07% | 0.83% | 1.24% | 1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |